CEN-101: Difference between revisions
From Proteopedia
Jump to navigationJump to search
| (19 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
[[Image:CEN-101.gif|right]] | [[Image:CEN-101.gif|"size=200"|test caption|right]] | ||
= | |||
=The Problem= | |||
The World Health Organization ranks bacterial resistance to antibiotics as one of the top three health care concerns worldwide, with staph bacterial infections being one of the largest contributors to this growing problem. | The World Health Organization ranks bacterial resistance to antibiotics as one of the top three health care concerns worldwide, with staph bacterial infections being one of the largest contributors to this growing problem. | ||
| Line 7: | Line 9: | ||
According to the CDC, of the estimated annual 2 million hospital-acquired infections in the US, approximately half are due to staph bacteria, including both methicillin-resistant as well as methicillin-sensitive S. aureus and S. epidermidis. | According to the CDC, of the estimated annual 2 million hospital-acquired infections in the US, approximately half are due to staph bacteria, including both methicillin-resistant as well as methicillin-sensitive S. aureus and S. epidermidis. | ||
=Biofilm Physiology= | =Biofilm Physiology= | ||
| Line 15: | Line 16: | ||
<ref name="Costerton">PMID:10334980</ref>. A growing body of peer reviewed publications supports the approach of attacking biofilm as an effective method to combat staph infections. | <ref name="Costerton">PMID:10334980</ref>. A growing body of peer reviewed publications supports the approach of attacking biofilm as an effective method to combat staph infections. | ||
It is now well know that staph must have a sufficient population (quorum) to allow them to form biofilms, enabling much improved survival in the host. Molecules involved in quorum sensing (QS) by Staphylococci like S. aureus include RNAIII activating protein (RAP), target of RAP (TRAP) and proteins encoded by the accessory gene regulator locus (agr), which ultimately initiate the expression of a myriad of virulence factors such as proteases, hemolysins and various other toxins | It is now well know that staph must have a sufficient population (quorum) to allow them to form biofilms, enabling much improved survival in the host. Molecules involved in quorum sensing (QS) by Staphylococci like S. aureus include RNAIII activating protein (RAP), target of RAP (TRAP) and proteins encoded by the accessory gene regulator locus (agr), which ultimately initiate the expression of a myriad of virulence factors such as proteases, hemolysins and various other toxins <ref name="Lowy">PMID: 9709046</ref> | ||
<ref name="March">PMID: 15464383</ref>. | |||
=The Solution= | =The Solution= | ||
StaphOff developed CEN-101 (also known as RIP or RNAIII Inhibiting Peptide), the first treatment for staph whose mechanism of action IS NOT to kill the bacteria. Rather, it eliminates the ability of these bacteria to form biofilms, to produce toxins and to survive. The molecule is a heptapeptide that can be delivered by a variety of dosing methods: (1) topical, (2) locally injectable, (3) intravenous administration, and (4) in solution as a medical device coating or in sterile locks. | StaphOff developed CEN-101 (also known as RIP or RNAIII Inhibiting Peptide), the first treatment for staph whose mechanism of action IS NOT to kill the bacteria. Rather, it eliminates the ability of these bacteria to form biofilms, to produce toxins and to survive. The molecule is a heptapeptide that can be delivered by a variety of dosing methods: (1) topical, (2) locally injectable, (3) intravenous administration, and (4) in solution as a medical device coating or in sterile locks. | ||
A large body of compelling evidence exists demonstrating that CEN-101 is effective in preventing and curing staph infections. In vitro data have been published in | A large body of compelling evidence exists demonstrating that CEN-101 is effective in preventing and curing staph infections. In vitro data have been published in eight peer reviewed articles. Twenty peer reviewed animal studies have been published for rats, mice, cows, and rabbits, all demonstrating that CEN-101 works effectively in a variety of applications (wound infections, graft associated infections, cellulitis, arthritis, sepsis, osteomyelitis and mastitis) with no observable side effects. Three articles about compassionate use in humans have also been published. All are part of a 323 patient compassionate care study of topical CEN-101, with a overall 91% improvement in outcome in advanced stage wound care patients (reduced number of amputations and reduced number of sepsis-related deaths)<ref>Wolcott, R., Lopez-Leban, F., Kiran, M. D. & Balaban, N. (2011). Wound Healing by an Anti-Staphylococcal Biofilm Approach, in <i>Biofilm Highlights</i> (Flemming, H.-C., Wingender, J. & Szewzyk, U., eds.), pp. 141-161, Springer, Heidelberg</ref><ref name="Lopez-Leban">PMID: 20963725</ref>. | ||
=References= | =References= | ||
<references/> | <references/> | ||
